Events | 2023.02.26
CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing
Majority of patients were attack free during the entire six-month treatment period (61.5%) Study results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions anticipated later in the calendar year Garadacimab underscores CSL\'s promise to develop innovative...
For more information, please visit
https://www.prnewswire.com/news-releases[...]-monthly-dosing-301756102.html
